

December 21, 2011

**Execution of a Pilot Study, Material Transfer and Evaluation Agreement
with OncoMed Pharmaceuticals, Inc.**

Tokyo-based biotech-venture company, Chiome Bioscience, Inc. announced that it has entered into a Pilot Study, Material Transfer and Evaluation Agreement with OncoMed Pharmaceuticals, Inc. of Redwood City, California. Under the agreement, Chiome and OncoMed will generate monoclonal antibodies with Chiome's proprietary ADLib[®] system for OncoMed's research use and evaluation. Financial terms are undisclosed.

"We are extremely delighted about entering into research collaboration with OncoMed," said Masa Fujiwara, CEO & President, of Chiome. "We believe that the combination of OncoMed's distinguished research and development activities in cancer stem cells with Chiome's innovative platform technology for antibody generation has the potential to accelerate drug discovery and advance pharmaceutical development which offers new treatment options in oncology field."

<About the ADLib[®] system>

The ADLib[®] system is an innovative technology for antibody generation by leveraging gene conversion of chicken DT40 cells. This technology features several advantages over the conventional methods. It generates antibodies quite fast, potentially in two weeks entirely in vitro. Also it generates antibodies with, theoretically, unlimited diversification, which allows for the development of much broader variety of antibodies than those may be obtained by currently available methods.

The ADLib[®] system could be a de facto standard platform technology in generating monoclonal antibodies.

<About Chiome Bioscience, Inc.>

Chiome Bioscience is a Japan-based biotech company specialized in antibody and technology development. It has developed an innovative and unique platform technology, ADLib[®] system, to which right Chiome co-owns with RIKEN Institute.

Chiome Bioscience is offering ADLib[®] system to partners under a nonexclusive license to maximize the value of the technology. By leveraging this proprietary technology Chiome Bioscience believes it can make great contributions to pharmaceutical development.

For more information about Chiome Bioscience, please visit its web site at

<http://www.chiome.co.jp/english/>

ADLib[®] is the trademark of Chiome Bioscience Inc. All rights are reserved.

<About OncoMed Therapeutics, Inc.>

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis. OncoMed has advanced three anticancer stem cell monoclonal antibodies into the clinic, OMP-21M18, OMP-59R5, and OMP-18R5, which target key cancer stem cell signaling pathways including Notch and Wnt. Additional information can be found at the company's website:

<http://www.oncomed.com>

SOURCE: Chiome Bioscience Inc.

CONTACT: Shigeru Kobayashi
Senior Director, Business Development
Chiome Bioscience Inc.
skobayashi@chiome.co.jp